28
Sep
meeting on the mesa

David Venables, CEO of Synpromics, will sit on the panel ‘Gene Therapy: Building the gene medicine pipeline through next generation technologies’ on the 4th October at the annual Partnering Forum, part of the Cell & Gene Meeting on the Mesa to be held October 4-6 in La Jolla, California.

20
Sep

Synpromics will provide key muscle-selective promoter candidates for the development of new treatment options for Duchenne muscular dystrophy (DMD).

19
Sep

At this year’s Bioprocessing Summit, Dr Graham Whyteside presented on 'Inducible synthetic promoters for the production of gene therapy viral vectors'. Synpromics has developed a novel proprietary inducible expression platform that provides exquisite and tuneable control of gene expression.

11
Sep
Roslin Innovation Centre

The new custom-built centre based at the University of Edinburgh’s allows us to meet increasing global demand for its cutting-edge gene control technology.

19
Apr

Synpromics, the leading synthetic promoter and gene control company, is pleased to announce that it has completed a financing round of £5.2M.

Pages